Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 8;12(22):6978.
doi: 10.3390/jcm12226978.

Chronic Obstructive Pulmonary Disease Overdiagnosis and Overtreatment: A Meta-Analysis

Matteo Fiore  1 , Matteo Ricci  1 , Annalisa Rosso  2 , Maria Elena Flacco  2 , Lamberto Manzoli  1
Affiliations
Review

Chronic Obstructive Pulmonary Disease Overdiagnosis and Overtreatment: A Meta-Analysis

Matteo Fiore et al. J Clin Med. .

Abstract

This meta-analysis of observational studies aimed at estimating the overall prevalence of overdiagnosis and overtreatment in subjects with a clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD). MedLine, Scopus, Embase and Cochrane databases were searched, and random-effect meta-analyses of proportions were stratified by spirometry criteria (Global Initiative for COPD (GOLD) or Lower Limit of Normal (LLN)), and setting (hospital or primary care). Forty-two studies were included. Combining the data from 39 datasets, including a total of 23,765 subjects, the pooled prevalence of COPD overdiagnosis, according to the GOLD definition, was 42.0% (95% Confidence Interval (CI): 37.3-46.8%). The pooled prevalence according to the LLN definition was 48.2% (40.6-55.9%). The overdiagnosis rate was higher in primary care than in hospital settings. Fourteen studies, including a total of 8183 individuals, were included in the meta-analysis estimating the prevalence of COPD overtreatment. The pooled rates of overtreatment according to GOLD and LLN definitions were 57.1% (40.9-72.6%) and 36.3% (17.8-57.2%), respectively. When spirometry is not used, a large proportion of patients are erroneously diagnosed with COPD. Approximately half of them are also incorrectly treated, with potential adverse effects and a massive inefficiency of resources allocation. Strategies to increase the compliance to current guidelines on COPD diagnosis are urgently needed.

Keywords: chronic obstructive pulmonary disease (COPD); meta-analysis; overdiagnosis; overtreatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart. From: Page MJ, McKenzie JE, Bossuyt PM, et al. “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews” [11].
Figure 2
Figure 2
Proportion meta-analysis of overdiagnosis among subjects with clinical diagnosis of COPD, according to GOLD definition [8,16,17,18,21,22,23,24,25,26,27,28,29,30,31,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56]. ES = Effect Size (% of overdiagnosis); CI: Confidence Interval; COPD: Clinically Diagnosed Chronic Obstructive Pulmonary Disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; I2: level of heterogeneity.
Figure 3
Figure 3
Proportion meta-analysis of overdiagnosis among subjects with clinical diagnosis of COPD, according to LLN definition [19,20,22,32,37,40,43,44,46,49]. ES = Effect Size (% of overdiagnosis); CI: Confidence Interval; COPD: Clinically Diagnosed Chronic Obstructive Pulmonary Disease; LLN: Lower limit of normal; I2: level of heterogeneity.
Figure 4
Figure 4
Proportion meta-analysis of overtreatment among overdiagnosed individuals, according to GOLD and LLN definition [8,19,20,23,25,26,39,46,50,51,53,54,55,56]. ES = Effect Size (% of overtreatment); CI: Confidence Interval; COPD: Clinically Diagnosed Chronic Obstructive Pulmonary Disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LLN: Lower limit of normal; I2: level of heterogeneity.
See this image and copyright information in PMC

References

    1. Safiri S., Carson-Chahhoud K., Noori M., Nejadghaderi S.A., Sullman M.J.M., Ahmadian Heris J., Ansarin K., Mansournia M.A., Collins G.S., Kolahi A.A., et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990–2019: Results from the Global Burden of Disease Study 2019. BMJ. 2022;378:e069679. doi: 10.1136/bmj-2021-069679. - DOI - PMC - PubMed
    1. Khakban A., Sin D.D., FitzGerald J.M., McManus B.M., Ng R., Hollander Z., Sadatsafavi M. The Projected Epidemic of Chronic Obstructive Pulmonary Disease Hospitalizations over the Next 15 Years. A Population-based Perspective. Am. J. Respir. Crit. Care Med. 2017;195:287–291. doi: 10.1164/rccm.201606-1162PP. - DOI - PubMed
    1. Doña E., Reinoso-Arija R., Carrasco-Hernandez L., Doménech A., Dorado A., Lopez-Campos J.L. Exploring Current Concepts and Challenges in the Identification and Management of Early-Stage COPD. J. Clin. Med. 2023;12:5293. doi: 10.3390/jcm12165293. - DOI - PMC - PubMed
    1. GOLD (Global Initiative for Obstructive Lung Disease) Spirometry for Health Care Providers. [(accessed on 6 July 2010)]. Available online: https://goldcopd.org/wp-content/uploads/2016/04/GOLD_Spirometry_2010.pdf.
    1. Fernandez-Villar A., Soriano J.B., Lopez-Campos J.L. Overdiagnosis of COPD: Precise definitions and proposals for improvement. Br. J. Gen. Pract. 2017;67:183–184. doi: 10.3399/bjgp17X690389. - DOI - PMC - PubMed

LinkOut - more resources